

# Emanuele Zucca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5039728/publications.pdf>

Version: 2024-02-01

133  
papers

20,589  
citations

43973

48  
h-index

14702

127  
g-index

134  
all docs

134  
docs citations

134  
times ranked

15168  
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Response Criteria for Malignant Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 579-586.	0.8	4,061
2	Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. <i>Journal of Clinical Oncology</i> , 2014, 32, 3059-3067.	0.8	3,729
3	Follicular Lymphoma International Prognostic Index. <i>Blood</i> , 2004, 104, 1258-1265.	0.6	1,552
4	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	0.8	1,269
5	Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5034-5043.	0.8	729
6	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet</i> , 2009, 374, 1512-1520.	6.3	588
7	Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. <i>Blood</i> , 2004, 103, 4416-4423.	0.6	531
8	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
9	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e217-e227.	2.2	442
10	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2003, 102, 2741-2745.	0.6	391
11	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e196-e204.	2.2	344
12	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1979-1983.	0.8	265
13	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	2.2	258
14	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. <i>Clinical Cancer Research</i> , 2015, 21, 1628-1638.	3.2	237
15	The NF- $\kappa$ B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. <i>Blood</i> , 2009, 113, 4918-4921.	0.6	232
16	Eradication of <i>Borrelia burgdorferi</i> infection in primary marginal zone B-cell lymphoma of the skin. <i>Human Pathology</i> , 2000, 31, 263-268.	1.1	227
17	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2413-2425.	0.6	223
18	The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. <i>Blood</i> , 2016, 127, 2082-2092.	0.6	219

#	ARTICLE	IF	CITATIONS
19	Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98. <i>Journal of Clinical Oncology</i> , 2010, 28, 4480-4484.	0.8	218
20	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 17-29.	0.6	197
21	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
22	Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). <i>Journal of Clinical Oncology</i> , 2015, 33, 2523-2529.	0.8	157
23	[ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.	0.8	149
24	A MALT lymphoma prognostic index. <i>Blood</i> , 2017, 130, 1409-1417.	0.6	149
25	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	0.8	143
26	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015, 126, 950-956.	0.6	138
27	Long-term outcome following <i>Helicobacter pylori</i> eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. <i>Annals of Oncology</i> , 2009, 20, 1086-1093.	0.6	130
28	Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. <i>Blood</i> , 2002, 99, 2541-2544.	0.6	110
29	Histologic transformation in marginal zone lymphomas. <i>Annals of Oncology</i> , 2015, 26, 2329-2335.	0.6	104
30	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. <i>Blood</i> , 2013, 122, 2683-2693.	0.6	98
31	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	3.2	92
32	Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas. <i>Clinical Cancer Research</i> , 2014, 20, 5207-5216.	3.2	91
33	Incidence, risk factors and outcome of histological transformation in follicular lymphoma. <i>British Journal of Haematology</i> , 2012, 157, 188-196.	1.2	89
34	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 552-560.	0.8	87
35	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
36	Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. <i>British Journal of Haematology</i> , 2013, 160, 47-52.	1.2	79

#	ARTICLE	IF	CITATIONS
37	Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. <i>Annals of Oncology</i> , 2013, 24, 1344-1351.	0.6	75
38	Genome wide DNA-profiling of HIV-related B-cell lymphomas. <i>British Journal of Haematology</i> , 2010, 148, 245-255.	1.2	70
39	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). <i>Annals of Oncology</i> , 2011, 22, 689-695.	0.6	64
40	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2018, 132, 179-186.	0.6	63
41	Chlorambucil versus observation after anti- <i>Helicobacter</i> therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. <i>British Journal of Haematology</i> , 2009, 144, 367-375.	1.2	60
42	Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1080-1088.	3.4	58
43	Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. <i>Blood</i> , 2001, 98, 781-786.	0.6	55
44	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. <i>Haematologica</i> , 2019, 104, e558-e561.	1.7	55
45	Rituximab in primary central nervous system lymphoma—A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	0.8	54
46	MATRix—RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e110-e121.	2.2	54
47	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	0.6	53
48	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). <i>BMC Cancer</i> , 2016, 16, 282.	1.1	53
49	Marginal-Zone Lymphomas. <i>New England Journal of Medicine</i> , 2022, 386, 568-581.	13.9	53
50	Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. <i>Journal of Clinical Oncology</i> , 2022, 40, 2352-2360.	0.8	53
51	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	1.9	52
52	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. <i>Haematologica</i> , 2013, 98, 357-363.	1.7	51
53	Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. <i>Journal of Clinical Oncology</i> , 2016, 34, 495-500.	0.8	49
54	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49

#	ARTICLE	IF	CITATIONS
55	A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT) Tj ETQq1 1 0.784314 rgBT /Over Oncology, 2016, 34, 177-183.	0.8	48
56	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Advances, 2020, 4, 1082-1092.	2.5	47
57	Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica, 2000, 85, 147-53.	1.7	47
58	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36, 1870-1878.	3.3	47
59	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 2019, 134, 353-362.	0.6	45
60	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clinical Cancer Research, 2019, 25, 5167-5176.	3.2	43
61	Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica, 2011, 96, 1064-1066.	1.7	42
62	Preclinical evaluation of the <scp>BET</scp> bromodomain inhibitor <scp>BAY</scp> 1238097 for the treatment of lymphoma. British Journal of Haematology, 2017, 178, 936-948.	1.2	42
63	Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALTâ€type gastric lymphoma B cells have undergone an antigen selection process. British Journal of Haematology, 1997, 97, 830-836.	1.2	41
64	Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. Leukemia and Lymphoma, 2007, 48, 104-108.	0.6	41
65	<scp><i>MYD88</i></scp> somatic mutations in <scp>MALT</scp> lymphomas. British Journal of Haematology, 2012, 158, 662-664.	1.2	41
66	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British Journal of Haematology, 2018, 183, 755-765.	1.2	41
67	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Advances, 2021, 5, 2375-2384.	2.5	40
68	MALT lymphomas: pathogenesis can drive treatment. Oncology, 2011, 25, 1134-42, 1147.	0.4	40
69	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Advances, 2020, 4, 4124-4135.	2.5	37
70	Recent advances in understanding the biology of marginal zone lymphoma. F1000Research, 2018, 7, 406.	0.8	35
71	Patterns of survival of follicular lymphomas at a single institution through three decades. Leukemia and Lymphoma, 2010, 51, 1028-1034.	0.6	33
72	Life expectancy of young adults with follicular lymphoma. Annals of Oncology, 2015, 26, 2317-2322.	0.6	31

#	ARTICLE	IF	CITATIONS
73	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.4	31
74	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. <i>Haematologica</i> , 2020, 105, 2592-2597.	1.7	29
75	Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response. <i>Oncotarget</i> , 2015, 6, 5059-5071.	0.8	29
76	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. <i>Haematologica</i> , 2019, 104, 1633-1639.	1.7	28
77	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. <i>Blood Advances</i> , 2020, 4, 819-829.	2.5	28
78	Management of the Marginal Zone Lymphomas. <i>Cancer Treatment and Research</i> , 2015, 165, 227-249.	0.2	27
79	Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. <i>Haematologica</i> , 2020, 105, 2584-2591.	1.7	27
80	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. <i>Annals of Oncology</i> , 2016, 27, 1123-1128.	0.6	26
81	Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 94-107.	1.1	26
82	Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. <i>Oncotarget</i> , 2016, 7, 58142-58147.	0.8	25
83	Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 590-598.	0.9	22
84	The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15th CML workshop on ctDNA. <i>Hematological Oncology</i> , 2020, 38, 34-37.	0.8	22
85	Marginal zone lymphoma: present status and future perspectives. <i>Haematologica</i> , 2022, 107, 35-43.	1.7	22
86	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2298-2303.	0.6	21
87	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439.	1.2	20
88	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18 FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. <i>British Journal of Haematology</i> , 2017, 178, 588-591.	1.2	20
89	Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. <i>Annals of Oncology</i> , 2018, 29, 332-340.	0.6	20
90	Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. <i>Annals of Oncology</i> , 2018, 29, 1120-1129.	0.6	18

#	ARTICLE	IF	CITATIONS
91	Toward New Treatments for Mantle-Cell Lymphoma?. <i>New England Journal of Medicine</i> , 2013, 369, 571-572.	13.9	17
92	Hepatitis C virus and GBV $\beta$ virus prevalence among patients with B $\beta$ cell lymphoma in different European regions: a case $\beta$ control study of the International Extranodal Lymphoma Study Group. <i>Hematological Oncology</i> , 2012, 30, 137-142.	0.8	16
93	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. <i>Cancers</i> , 2019, 11, 775.	1.7	14
94	Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1334-1344.	3.3	14
95	Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B $\beta$ cell lymphoma: post $\beta$ hoc analysis from the SAKK38/07 clinical trial. <i>Hematological Oncology</i> , 2020, 38, 715-725.	0.8	14
96	Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy $\beta$ free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). <i>British Journal of Haematology</i> , 2021, 192, 1031-1034.	1.2	14
97	Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. <i>British Journal of Haematology</i> , 2020, 189, 707-717.	1.2	13
98	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R $\beta$ CHOP14: A SAKK 38/07 trial post $\beta$ hoc analysis. <i>Hematological Oncology</i> , 2022, 40, 12-22.	0.8	13
99	Single and combined BTK and PI3K $\beta$ inhibition with acalabrutinib and ACP $\beta$ 19 in pre $\beta$ clinical models of aggressive lymphomas. <i>British Journal of Haematology</i> , 2019, 187, 595-601.	1.2	12
100	Absence of <i>NOTCH1</i> gene mutations in MALT lymphomas. <i>British Journal of Haematology</i> , 2012, 157, 382-384.	1.2	11
101	Follicular lymphoma: State $\beta$ of $\beta$ the $\beta$ art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , 2017, 35, 397-407.	0.8	11
102	Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 71-76.	0.6	10
103	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. <i>Blood Advances</i> , 2021, 5, 2467-2480.	2.5	10
104	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. <i>Blood Advances</i> , 2021, 5, 4674-4685.	2.5	10
105	Diagnosis and treatment of follicular lymphoma. <i>Swiss Medical Weekly</i> , 2011, 141, w13247.	0.8	10
106	Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. <i>Blood Advances</i> , 2020, 4, 5951-5957.	2.5	9
107	Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial. <i>British Journal of Haematology</i> , 2020, 190, e258-e261.	1.2	9
108	THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA $\beta$ TRANSFORMED $\beta$ BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. <i>Hematological Oncology</i> , 2017, 35, 115-116.	0.8	8



#	ARTICLE	IF	CITATIONS
109	FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. <i>Hematological Oncology</i> , 2019, 37, 224-225.	0.8	7
110	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. <i>Cancers</i> , 2022, 14, 1018.	1.7	7
111	METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA.. <i>Hematological Oncology</i> , 2017, 35, 60-61.	0.8	5
112	PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY- $\alpha$ FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK).. <i>Hematological Oncology</i> , 2019, 37, 111-112.	0.8	5
113	A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVALUATING SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB IN RICHTER TRANSFORMATION FROM CLL. <i>Hematological Oncology</i> , 2019, 37, 557-558.	0.8	5
114	Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. <i>Hematological Oncology</i> , 2021, 39, 196-204.	0.8	5
115	SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, e2016062.	0.5	4
116	Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. <i>Hematological Oncology</i> , 2018, 36, 757-764.	0.8	4
117	SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 3911-3920.	2.5	4
118	Novel acquisitions on biology and management of transformed follicular lymphoma. <i>Hematological Oncology</i> , 2018, 36, 617-623.	0.8	3
119	Radiomics in Malignant Lymphomas. , 0, , 71-82.		3
120	Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials. <i>Leukemia and Lymphoma</i> , 2022, 63, 1544-1555.	0.6	3
121	The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, 586-601.	0.5	3
122	$\text{max}$ : A simple and reliable PET/CT-derived new biomarker of lymphoma outcome?. <i>Hematological Oncology</i> , 2022, 40, 843-845.	0.8	3
123	A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 60-65.	0.8	2
124	Use of epirubicin to treat diffuse large B-cell lymphoma. <i>Lancet Haematology</i> , the, 2019, 6, e292-e293.	2.2	1
125	Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03. <i>Blood</i> , 2018, 132, 1601-1601.	0.6	1
126	A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7575-TPS7575.	0.8	1



#	ARTICLE	IF	CITATIONS
127	Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 1100-1104.	0.8	1
128	Reply to the letter to the editor "Survival in young adults diagnosed with follicular lymphoma" by Calvo et al.. <i>Annals of Oncology</i> , 2016, 27, 1173.	0.6	0
129	PET imaging of lymphomas. , 2021, , .		0
130	ECF can be used as adjuvant treatment for oesophagogastric adenocarcinoma: A two-institutions experience. <i>Journal of Clinical Oncology</i> , 2004, 22, 4251-4251.	0.8	0
131	Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	0
132	Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method. <i>Hematological Oncology</i> , 2022, 40, 1086-1089.	0.8	0
133	ECF can be used as adjuvant treatment for oesophagogastric adenocarcinoma: A two-institutions experience. <i>Journal of Clinical Oncology</i> , 2004, 22, 4251-4251.	0.8	0